Product introduction：
CAS: 367514-88-3
Appearance: white to off-white powder.
MF: C28H36N4O2S
MW: 492.684
Mp: 243-248℃
Assay: ≥99.0%
Solubility: It is very slightly soluble in water, practically insoluble or insoluble in 0.1 N HCl, slightly soluble in ethanol, sparingly soluble in methanol, practically insoluble or insoluble in toluene very slightly soluble in acetone and has a pKa of 7.6.
Application: Lurasidone hcl powder cas 367514-88-3 is an atypical antipsychotic belonging to the chemical class of benzisothiazol derivatives. Lurasidone hcl powder cas 367514-88-3 (Latuda) belongs to a class of medications known as atypical antipsychotics. Other members of this class include clozapine (Clozaril), risperidone (Risperdal), aripiprazole (Abilify) and ziprasidone (Geodon). Atypical antipsychotics like lurasidone are considered the standard of care for treating schizophrenia. Additionally, in clinical studies lurasidone was shown to be effective in improving mood in many people struggling with bipolar depression. Lurasidone can be taken alone or with either lithium (Lithobid) or valproate (Depakote).
Lurasidone hcl powder cas 367514-88-3 was approved for the treatment of schizophrenia in adults in October, 2010. Almost three years later in July, 2012 the FDA approved lurasidone for the treatment of depressive episodes associated with bipolar I disorder.
Other chemical names: LATUDA, Exodiene Lurasidone, Lurasidone HCl / Lurasidone Hydrochloride, (3aR,4R,7S,7aS)-2-(((1R,2R)-2-((4-(benzo[d]isothiazol-3-yl), SM-13496 (Hydrochloride).
